Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Target Price at $12.33

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has been given an average recommendation of "Buy" by the six research firms that are covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $12.33.

Several equities analysts have recently issued reports on RANI shares. Canaccord Genuity Group reiterated a "buy" rating and set a $9.00 target price on shares of Rani Therapeutics in a report on Wednesday, February 26th. HC Wainwright reiterated a "buy" rating and set a $9.00 price objective on shares of Rani Therapeutics in a research note on Thursday, April 3rd.

Rani Therapeutics Stock Down 2.7 %

Shares of RANI stock traded down $0.03 during midday trading on Thursday, reaching $1.09. 141,655 shares of the stock were exchanged, compared to its average volume of 729,801. The firm has a market cap of $62.66 million, a PE ratio of -1.03 and a beta of 0.24. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 2.34. The company's 50 day moving average is $1.37 and its two-hundred day moving average is $1.67. Rani Therapeutics has a 1 year low of $1.02 and a 1 year high of $7.88.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). The firm had revenue of $1.03 million for the quarter. On average, equities research analysts predict that Rani Therapeutics will post -1.01 EPS for the current year.

Institutional Investors Weigh In On Rani Therapeutics

Large investors have recently bought and sold shares of the business. CWA Asset Management Group LLC bought a new stake in shares of Rani Therapeutics in the first quarter worth approximately $105,000. Two Sigma Advisers LP purchased a new stake in Rani Therapeutics in the fourth quarter worth approximately $151,000. Two Sigma Investments LP bought a new stake in Rani Therapeutics in the 4th quarter worth approximately $399,000. Insigneo Advisory Services LLC purchased a new stake in Rani Therapeutics during the 4th quarter valued at $65,000. Finally, Takeda Pharmaceutical Co. Ltd. bought a new position in shares of Rani Therapeutics during the 4th quarter valued at $278,000. 30.19% of the stock is currently owned by institutional investors.

Rani Therapeutics Company Profile

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.